Review





Similar Products

gapdh  (Proteintech)
94
Proteintech gapdh
Gapdh, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gapdh/product/Proteintech
Average 94 stars, based on 1 article reviews
gapdh - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
sars cov 2 n  (Proteintech)
93
Proteintech sars cov 2 n
Sars Cov 2 N, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sars cov 2 n/product/Proteintech
Average 93 stars, based on 1 article reviews
sars cov 2 n - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
sars cov 2 spike glycoprotein coronavirus rabbit  (Proteintech)
94
Proteintech sars cov 2 spike glycoprotein coronavirus rabbit
Sars Cov 2 Spike Glycoprotein Coronavirus Rabbit, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sars cov 2 spike glycoprotein coronavirus rabbit/product/Proteintech
Average 94 stars, based on 1 article reviews
sars cov 2 spike glycoprotein coronavirus rabbit - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
mouse anti sars cov 2 spike monoclonal antibodies  (Proteintech)
94
Proteintech mouse anti sars cov 2 spike monoclonal antibodies
Mouse Anti Sars Cov 2 Spike Monoclonal Antibodies, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti sars cov 2 spike monoclonal antibodies/product/Proteintech
Average 94 stars, based on 1 article reviews
mouse anti sars cov 2 spike monoclonal antibodies - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
anti spike protein sars cov 2 antibody  (Proteintech)
94
Proteintech anti spike protein sars cov 2 antibody
Anti Spike Protein Sars Cov 2 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti spike protein sars cov 2 antibody/product/Proteintech
Average 94 stars, based on 1 article reviews
anti spike protein sars cov 2 antibody - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
rbd  (Proteintech)
94
Proteintech rbd
Seropositivity rates (A) and anti-S-receptor-binding domain <t>(anti-S-RBD)</t> <t>immunoglobulin</t> <t>(IgG)</t> titers (B) after immunization of chronic hepatitis B (CHB) patients with the inactivated SARS-CoV-2 vaccine in the week 1, 2, 4, 8, 12, and ≥16 subgroups. These subgroups included samples collected at 7 ± 2, 14 ± 2, 28 ± 7, 56 ± 14, 71–98, and ≥112 days after the second vaccination, respectively.
Rbd, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rbd/product/Proteintech
Average 94 stars, based on 1 article reviews
rbd - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
sars cov 2 n antibody test  (Proteintech)
94
Proteintech sars cov 2 n antibody test
Seropositivity rates (A) and anti-S-receptor-binding domain <t>(anti-S-RBD)</t> <t>immunoglobulin</t> <t>(IgG)</t> titers (B) after immunization of chronic hepatitis B (CHB) patients with the inactivated SARS-CoV-2 vaccine in the week 1, 2, 4, 8, 12, and ≥16 subgroups. These subgroups included samples collected at 7 ± 2, 14 ± 2, 28 ± 7, 56 ± 14, 71–98, and ≥112 days after the second vaccination, respectively.
Sars Cov 2 N Antibody Test, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sars cov 2 n antibody test/product/Proteintech
Average 94 stars, based on 1 article reviews
sars cov 2 n antibody test - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
sars cov 2 spike  (Proteintech)
94
Proteintech sars cov 2 spike
Seropositivity rates (A) and anti-S-receptor-binding domain <t>(anti-S-RBD)</t> <t>immunoglobulin</t> <t>(IgG)</t> titers (B) after immunization of chronic hepatitis B (CHB) patients with the inactivated SARS-CoV-2 vaccine in the week 1, 2, 4, 8, 12, and ≥16 subgroups. These subgroups included samples collected at 7 ± 2, 14 ± 2, 28 ± 7, 56 ± 14, 71–98, and ≥112 days after the second vaccination, respectively.
Sars Cov 2 Spike, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sars cov 2 spike/product/Proteintech
Average 94 stars, based on 1 article reviews
sars cov 2 spike - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

Image Search Results


Seropositivity rates (A) and anti-S-receptor-binding domain (anti-S-RBD) immunoglobulin (IgG) titers (B) after immunization of chronic hepatitis B (CHB) patients with the inactivated SARS-CoV-2 vaccine in the week 1, 2, 4, 8, 12, and ≥16 subgroups. These subgroups included samples collected at 7 ± 2, 14 ± 2, 28 ± 7, 56 ± 14, 71–98, and ≥112 days after the second vaccination, respectively.

Journal: Frontiers in Immunology

Article Title: Antibody response and safety of inactivated SARS-CoV-2 vaccines in chronic hepatitis B patients with and without cirrhosis

doi: 10.3389/fimmu.2023.1167533

Figure Lengend Snippet: Seropositivity rates (A) and anti-S-receptor-binding domain (anti-S-RBD) immunoglobulin (IgG) titers (B) after immunization of chronic hepatitis B (CHB) patients with the inactivated SARS-CoV-2 vaccine in the week 1, 2, 4, 8, 12, and ≥16 subgroups. These subgroups included samples collected at 7 ± 2, 14 ± 2, 28 ± 7, 56 ± 14, 71–98, and ≥112 days after the second vaccination, respectively.

Article Snippet: Indirect ELISA was used to detect the IgG antibodies against the RBD of the SARS-CoV-2 spike protein (anti-S-RBD IgG) according to the manufacturer’s protocol (KE30003; Proteintech, Wuhan, China).

Techniques: Binding Assay

Seropositivity rates (A) and anti-S-receptor-binding domain (anti-S-RBD) immunoglobulin G (IgG) titers (B) after immunization of chronic hepatitis B (CHB) patients with the inactivated SARS-CoV-2 vaccine in the week 1, 2, 4, 8, 12, and ≥16 subgroups after adjusting for age, sex, and interval between vaccination and blood collection. These subgroups included samples collected at 7 ± 2, 14 ± 2, 28 ± 7, 56 ± 14, 71–98, and ≥112 days after the second vaccination, respectively. * p < 0.05.

Journal: Frontiers in Immunology

Article Title: Antibody response and safety of inactivated SARS-CoV-2 vaccines in chronic hepatitis B patients with and without cirrhosis

doi: 10.3389/fimmu.2023.1167533

Figure Lengend Snippet: Seropositivity rates (A) and anti-S-receptor-binding domain (anti-S-RBD) immunoglobulin G (IgG) titers (B) after immunization of chronic hepatitis B (CHB) patients with the inactivated SARS-CoV-2 vaccine in the week 1, 2, 4, 8, 12, and ≥16 subgroups after adjusting for age, sex, and interval between vaccination and blood collection. These subgroups included samples collected at 7 ± 2, 14 ± 2, 28 ± 7, 56 ± 14, 71–98, and ≥112 days after the second vaccination, respectively. * p < 0.05.

Article Snippet: Indirect ELISA was used to detect the IgG antibodies against the RBD of the SARS-CoV-2 spike protein (anti-S-RBD IgG) according to the manufacturer’s protocol (KE30003; Proteintech, Wuhan, China).

Techniques: Binding Assay

Comparison of the antibody responses according to age, sex, and body mass index (BMI). (A) Seropositivity rates. (B) Anti-S-receptor-binding domain (anti-S-RBD) immunoglobulin G (IgG) titers. * p < 0.05.

Journal: Frontiers in Immunology

Article Title: Antibody response and safety of inactivated SARS-CoV-2 vaccines in chronic hepatitis B patients with and without cirrhosis

doi: 10.3389/fimmu.2023.1167533

Figure Lengend Snippet: Comparison of the antibody responses according to age, sex, and body mass index (BMI). (A) Seropositivity rates. (B) Anti-S-receptor-binding domain (anti-S-RBD) immunoglobulin G (IgG) titers. * p < 0.05.

Article Snippet: Indirect ELISA was used to detect the IgG antibodies against the RBD of the SARS-CoV-2 spike protein (anti-S-RBD IgG) according to the manufacturer’s protocol (KE30003; Proteintech, Wuhan, China).

Techniques: Binding Assay

Comparison of the overall antibody response between patients with normal and abnormal liver function. (A) Seropositivity rates. (B) Anti-S-receptor-binding domain (anti-S-RBD) immunoglobulin G (IgG) titers. ** p < 0.01; *** p ≤ 0.001.

Journal: Frontiers in Immunology

Article Title: Antibody response and safety of inactivated SARS-CoV-2 vaccines in chronic hepatitis B patients with and without cirrhosis

doi: 10.3389/fimmu.2023.1167533

Figure Lengend Snippet: Comparison of the overall antibody response between patients with normal and abnormal liver function. (A) Seropositivity rates. (B) Anti-S-receptor-binding domain (anti-S-RBD) immunoglobulin G (IgG) titers. ** p < 0.01; *** p ≤ 0.001.

Article Snippet: Indirect ELISA was used to detect the IgG antibodies against the RBD of the SARS-CoV-2 spike protein (anti-S-RBD IgG) according to the manufacturer’s protocol (KE30003; Proteintech, Wuhan, China).

Techniques: Binding Assay